Induction immunosuppression in kidney transplant recipients with HIV: To deplete or not to deplete?
- PMID: 38953433
- DOI: 10.1111/tid.14299
Induction immunosuppression in kidney transplant recipients with HIV: To deplete or not to deplete?
Comment on
-
Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency.Transpl Infect Dis. 2024 Aug;26(4):e14287. doi: 10.1111/tid.14287. Epub 2024 May 2. Transpl Infect Dis. 2024. PMID: 38698669 Free PMC article.
References
REFERENCES
-
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853‐860.
-
- Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27‐34.
-
- Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV‐infected recipients. N Engl J Med. 2010;363(21):2004‐2014.
-
- Sparkes T, Manitpisitkul W, Masters B, et al. Impact of antiretroviral regimen on renal transplant outcomes in HIV‐infected recipients. Transpl Infect Dis. 2018;20(6):e12992.
-
- Cooper M, Dunne I, Kuten S, et al. Impact of protease inhibitor‐based antiretroviral therapy on tacrolimus intrapatient variability in HIV‐positive kidney transplant recipients. Transplant Proc. 2021;53(3):984‐988.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
